J Endocr Surg.  2017 Sep;17(3):122-130. 10.16956/jes.2017.17.3.122.

Diagnostic Accuracy of PET/MR for Evaluating Central Lymph Node Status in Patients with Papillary Thyroid Carcinoma

• Byeon YH
• Choi JE
• Park JY
• Song JH
• Yeo KJ
• Kong EJ
• Kang SH
• Lee SJ

• KMID: 2389592
• DOI: http://doi.org/10.16956/jes.2017.17.3.122

Abstract

PURPOSE
Ultrasonography and computed tomography of the neck are commonly used for preoperative evaluation of neck lymph node (LN) status in papillary thyroid carcinoma (PTC). This study evaluated the accuracy of preoperative positron emission tomography/magnetic resonance (PET/MR) imaging of cervical LN status in PTC.
METHODS
A retrospective chart review of 285 patients who received PET/MR and underwent open thyroidectomy due to primary PTC between August 2012 and October 2013 was performed. Visual ¹â¸F-fluorodeoxyglucose uptake and preoperative morphologic abnormalities of nodal shape, cortical thickness, and the fatty hilum of neck nodes were analyzed using PET/MR imaging.
RESULTS
Total thyroidectomy and lobectomy were conducted in 78.2% (223/285) and 21.8% (62/285) of cases, respectively. The status of central neck LN were evaluated in all patients during surgery and additional evaluation of lateral neck LN were conducted in 11.9% (34/285) of patients through selective sampling or modified radical neck dissection. In total, 36.1% (103/285) of patients had pathologic neck LN metastasis (LNM). PET/MR imaging showed an accuracy of 68.8%, sensitivity of 32.7%, and specificity of 88.6% for the detection of central neck LNM; moreover, an accuracy of 95.1%, sensitivity 68.4%, and specificity of 97.0% for lateral neck LNM. PET/MR imaging showed higher accuracy for detecting neck LNM in the 164 patients who did not have suspected clinical thyroiditis than others.
CONCLUSION
PET/MR has a high specificity for detecting central LNM, especially for patients diagnosed with PTC without pathologic thyroiditis.

Keyword

Lymphatic metastasis; Thyroid neoplasms; Positron-emission tomography

MeSH Terms

Electrons
Humans
Lymph Nodes*
Lymphatic Metastasis
Neck
Neck Dissection
Neoplasm Metastasis
Positron-Emission Tomography
Retrospective Studies
Sensitivity and Specificity
Thyroid Gland*
Thyroid Neoplasms*
Thyroidectomy
Thyroiditis
Ultrasonography

Reference

1.Sampson E., Brierley JD., Le LW., Rotstein L., Tsang RW. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer. 2007. 110:1451–6.

2.Kim SK., Chai YJ., Park I., Woo JW., Lee JH., Lee KE, et al. Nomogram for predicting central node metastasis in papillary thyroid carcinoma. J Surg Oncol. 2017. 115:266–72.

3.Randolph GW., Duh QY., Heller KS., LiVolsi VA., Mandel SJ., Steward DL, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012. 22:1144–52.

4.Haugen BR., Alexander EK., Bible KC., Doherty GM., Mandel SJ., Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016. 26:1–133.

5.Ducoudray R., Trésallet C., Godiris-Petit G., Tissier F., Leenhardt L., Menegaux F. Prophylactic lymph node dissection in papillary thyroid carcinoma: is there a place for lateral neck dissection? World J Surg. 2013. 37:1584–91.

6.Ito Y., Tomoda C., Uruno T., Takamura Y., Miya A., Kobayashi K, et al. Clinical significance of metastasis to the central compartment from papillary microcarcinoma of the thyroid. World J Surg. 2006. 30:91–9.

7.Choi JS., Kim J., Kwak JY., Kim MJ., Chang HS., Kim EK. Preoperative staging of papillary thyroid carcinoma: comparison of ultrasound imaging and CT. AJR Am J Roentgenol. 2009. 193:871–8.

8.Antoch G., Bockisch A. Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging. 2009. 36(Suppl 1):S113–20.

9.Kim E., Park JS., Son KR., Kim JH., Jeon SJ., Na DG. Preoperative diagnosis of cervical metastatic lymph nodes in papillary thyroid carcinoma: comparison of ultrasound, computed tomography, and combined ultrasound with computed tomography. Thyroid. 2008. 18:411–8.

10.Som PM., Brandwein M., Lidov M., Lawson W., Biller HF. The varied presentations of papillary thyroid carcinoma cervical nodal disease: CT and MR findings. AJNR Am J Neuroradiol. 1994. 15:1123–8.

11.Lin X., Chen X., Jiru Y., Du J., Zhao G., Wu Z. Evaluating the influence of prophylactic central neck dissection on TNM staging and the recurrence risk stratification of cN0 differentiated thyroid carcinoma. Bull Cancer. 2016. 103:535–40.

12.Vaccarella S., Franceschi S., Bray F., Wild CP., Plummer M., Dal Maso L. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med. 2016. 375:614–7.

13.Leenhardt L., Erdogan MF., Hegedus L., Mandel SJ., Paschke R., Rago T, et al. 2013 European Thyroid Association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. Eur Thyroid J. 2013. 2:147–59.

14.Lee DW., Ji YB., Sung ES., Park JS., Lee YJ., Park DW, et al. Roles of ultrasonography and computed tomography in the surgical management of cervical lymph node metastases in papillary thyroid carcinoma. Eur J Surg Oncol. 2013. 39:191–6.

15.Dietlein M., Scheidhauer K., Voth E., Theissen P., Schicha H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1997. 24:1342–8.

16.Grünwald F., Kälicke T., Feine U., Lietzenmayer R., Scheidhauer K., Dietlein M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med. 1999. 26:1547–52.

17.Rischpler C., Nekolla SG., Dregely I., Schwaiger M. Hybrid PET/MR imaging of the heart: potential, initial experiences, and future prospects. J Nucl Med. 2013. 54:402–15.

18.Martinez-Möller A., Eiber M., Nekolla SG., Souvatzoglou M., Drzezga A., Ziegler S, et al. Workflow and scan protocol considerations for integrated whole-body PET/MRI in oncology. J Nucl Med. 2012. 53:1415–26.

19.Binse I., Poeppel TD., Ruhlmann M., Gomez B., Umutlu L., Bockisch A, et al. Imaging with (124)I in differentiated thyroid carcinoma: is PET/MRI superior to PET/CT? Eur J Nucl Med Mol Imaging. 2016. 43:1011–7.

20.Dercle L., Deandreis D., Terroir M., Leboulleux S., Lumbroso J., Schlumberger M. Evaluation of (124)I PET/CT and (124)I PET/MRI in the management of patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2016. 43:1006–10.

21.Hempel JM., Kloeckner R., Krick S., Pinto Dos Santos D., Schadmand-Fischer S., Boeßert P, et al. Impact of combined FDG-PET/CT and MRI on the detection of local recurrence and nodal metastases in thyroid cancer. Cancer Imaging. 2016. 16:37.

22.Jung JH., Kim CY., Son SH., Kim DH., Jeong SY., Lee SW, et al. Preoperative prediction of cervical lymph node metastasis using primary tumor SUVmax on 18F-FDG PET/CT in patients with papillary thyroid carcinoma. PLoS One. 2015. 10:e0144152.

23.Jeong HS., Baek CH., Son YI., Choi JY., Kim HJ., Ko YH, et al. Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CT. Clin Endocrinol (Oxf). 2006. 65:402–7.

24.Lim RS., Ramdave S., Beech P., Billah B., Karim MN., Smith JA, et al. Utility of SUVmax on (18) F-FDG PET in detecting cervical nodal metastases. Cancer Imaging. 2016. 16:39.